{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:03:00Z","timestamp":1746504180405,"version":"3.40.4"},"reference-count":33,"publisher":"ALUNA","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Aim: This preclinical study was oriented towards evaluating the efficiency of newly developed antibiotics against a selection of multi-drug-resistant Staphylococcus aureus strains, with the broader aim of finding a potent candidate to counteract the increasing resistance issue.\nMaterials and Methods: The study utilized four distinct strains of multi-drug-resistant Staphylococcus aureus (SA-1 to SA-4) and three novel antibiotics (NA-1 to NA-3) under controlled laboratory conditions. The bacterial strains were cultured in vitro, and a series of tests including drug susceptibility testing and the determination of minimum inhibitory concentrations (MIC) were conducted. Statistical analysis was carried out using two-way ANOVA and Bonferroni post-hoc tests to analyze the significance of the observed results.\nResults: Our data showcased variations in the growth characteristics and resistance profiles of the different strains, helping in identifying the most potent antibiotic among the tested compounds. Notably, antibiotic NA-1 manifested the lowest MIC values against the strains SA-1 and SA-3, indicating a higher potency (p &lt; 0.01). Moreover, NA-1 exhibited significantly lower MIC\u2085\u2080 and MIC\u2089\u2080 values (0.56 \u03bcg\/mL and 0.95 \u03bcg\/mL, respectively), suggesting that it had the best inhibitory power amongst the antibiotics tested against a majority of the strains (p &lt; 0.05).\nConclusions: The findings from this preclinical in-vitro study accentuate the potential of novel antibiotic NA-1 as a promising candidate in combatting multidrug-resistant Staphylococcus aureus strains. However, further research, including in-vivo studies, is requisite to substantiate the efficacy of this antibiotic in a clinical setting.<\/jats:p>","DOI":"10.36740\/merkur202502108","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:48:11Z","timestamp":1746445691000},"page":"203-211","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of novel antibiotics against multi-drug-resistant Staphylococcus aureus: a preclinical in vitro study"],"prefix":"10.36740","volume":"53","author":[{"given":"Baraa Bahaa","family":"Aldin","sequence":"first","affiliation":[{"name":"AL-MUSSAIB TECHNICAL INSTITUTE, AL-FURAT AL-AWSAT TECHNICAL UNIVERSITY, MUSSAIB, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa Nihad Abed","family":"Shubar","sequence":"additional","affiliation":[{"name":"AL-MUSSAIB TECHNICAL INSTITUTE, AL-FURAT AL-AWSAT TECHNICAL UNIVERSITY, MUSSAIB, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba","family":"Khalaf","sequence":"additional","affiliation":[{"name":"AL-MUSSAIB TECHNICAL INSTITUTE, AL-FURAT AL-AWSAT TECHNICAL UNIVERSITY, MUSSAIB, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Abreu AC, McBain AJ, Simoes M. Plants as sources of new antimicrobials and resistance-modifying agents. Natur Prod Rep. 2012; 29(9):1007-1021. doi: 10.1039\/c2np20035j.","DOI":"10.1039\/c2np20035j"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microb Antimicrob. 2013;12:1-15. doi: 10.1186\/1476-0711-12-22.","DOI":"10.1186\/1476-0711-12-22"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Bradford PA, Miller AA, O\u2019Donnell J, Mueller JP. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis. 2020;6(6):1332-1345. doi: 10.1021\/acsinfecdis.0c00021.","DOI":"10.1021\/acsinfecdis.0c00021"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Butler MS, Buss AD. Natural products \u2013 the future scaffolds for novel antibiotics? Biochem Pharmacol. 2006;71(7): 919-929. doi: 10.1016\/j.bcp.2005.10.012.","DOI":"10.1016\/j.bcp.2005.10.012"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Sources of novel antibiotics \u2013 aside the common roads. Appl Microb Biotechnol. 2010;88(6):1261-1267. doi: 10.1007\/s00253-010-2877-8.","DOI":"10.1007\/s00253-010-2877-8"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Douglas EJ, Wulandari SW, Lovell SD, Laabei M. Novel antimicrobial strategies to treat multi\u2010drug-resistant Staphylococcus aureus infections. Microb Biotechnol. 2023 Jul;16(7):1456-1474. doi: 10.1111\/1751-7915.14268.","DOI":"10.1111\/1751-7915.14268"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Drago L, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics\u2019 combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis. 2007;7(1):1-7. doi: 10.1186\/1471-2334-7-111.","DOI":"10.1186\/1471-2334-7-111"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Duplessis C, Warawa JM, Lawrenz MB, Henry M, Biswas B. Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug-Resistant Pseudomonas aeruginosa Murine Model. Antibiotics (Basel). 2021 Aug 5;10(8):946. doi: 10.3390\/antibiotics10080946.","DOI":"10.3390\/antibiotics10080946"},{"key":"ref8","unstructured":"9. Aledari M, Alzamili R, Kadim M, Alwan AA, Afshari JT, Darban RA. Thromboangiitis Obliterans or Buerger\u2019s Disease: Important Characteristics. J Pharm Negat Res. 2023;14:232-248. doi 10.47750\/pnr.2023.14.S01.26"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Alwan AM, Afshari JT. In Vivo Growth Inhibition of Human Caucasian Prostate Adenocarcinoma in Nude Mice Induced by Amygdalin with Metabolic Enzyme Combinations. BioMed Res Int. 2022 May 21: 2022: 4767621. doi: 10.1155\/2022\/4767621.","DOI":"10.1155\/2022\/4767621"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Younis W, Thangamani S, Seleem MN. Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections. Curr Pharm Des. 2015; 21(28): 4106-4111. doi: 10.2174\/1381612821666150506154434.","DOI":"10.2174\/1381612821666150506154434"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Vuong C, Yeh AJ, Cheung GY, Otto M. Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs. 2016; 25(1): 73-93. doi: 10.1517\/13543784.2016.1109077.","DOI":"10.1517\/13543784.2016.1109077"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Veeraraghavan B, Bakthavatchalam YD, Manesh A, et al. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care. Indian J Med Microbiol. 2023 Jan-Feb;41:71-80. doi: 10.1016\/j.ijmmb.2022.11.005.","DOI":"10.1016\/j.ijmmb.2022.11.005"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Vanamala K, Tatiparti K, Bhise K, Sau S, Scheetz MH, Rybak MJ, Andes D, Iyer AK. Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discov Today. 2021 Jan;26(1):31-43. doi: 10.1016\/j.drudis.2020.10.011.","DOI":"10.1016\/j.drudis.2020.10.011"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Skwor TA, Klemm S, Zhang H, Schardt B, Blaszczyk S, Matthew A, et al., Photodynamic inactivation of methicillin-resistant Staphylococcus aureus and Escherichia coli: A metalloporphyrin comparison. J Photochem Photobiol B. 2016;165:51-57. https:\/\/doi.org\/10.1016\/j.jphotobiol.2016.10.016","DOI":"10.1016\/j.jphotobiol.2016.10.016"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Rosa LP, da Silva FC, Nader SA, Meira GA, Viana MS. Antimicrobial photodynamic inactivation of Staphylococcus aureus biofilms in bone specimens using methylene blue, toluidine blue ortho and malachite green: an in vitro study. Arch Oral Biol. 2015;60(5):675-680. doi: 10.1016\/j.archoralbio.2015.02.010.","DOI":"10.1016\/j.archoralbio.2015.02.010"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Riool M, de Breij A, Kwakman PHS, et al. Thrombocidin-1-derived antimicrobial peptide TC19 combats superficial multi-drug resistant bacterial wound infections. Biochim Biophys Acta Biomemb. 2020 Aug 1;1862(8): 183282. doi: 10.1016\/j.bbamem.2020.183282.","DOI":"10.1016\/j.bbamem.2020.183282"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Richter K. Tackling superbugs in their slime castles: innovative approaches against antimicrobial-resistant biofilm infections. Microbiology Australia 2019; 40(4):165168.","DOI":"10.1071\/ma19049"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Princiotto S, Mazzini S, Musso L, et al. New Antimicrobials Based on the Adarotene Scaffold with Activity against Multi-Drug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Antibiotics (Basel). 2021 Jan 28;10(2):126. doi: 10.3390\/antibiotics10020126.","DOI":"10.3390\/antibiotics10020126"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Precit MR, Snavely EA, Liesman RM. Don\u2019t Be So Negative; Let\u2019s Have a Positive Perspective! A Review of Novel Antibiotics Targeting Gram-Positive Bacteria. Clin Microbiol Newslet. 2022; 44(24): 219-228. doi: 10.1016\/j.clinmicnews.2022.12.001","DOI":"10.1016\/j.clinmicnews.2022.12.001"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Fernandes P, Martens E. Antibiotics in late clinical development. Biochemi Pharmacol. 2017;133:152-163. doi: 10.1016\/j.bcp.2016.09.025.","DOI":"10.1016\/j.bcp.2016.09.025"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria \u2013 Time to react is now. Drug Resist Updt. 2011;14(2):118-124. doi: 10.1016\/j.drup.2011.02.003.","DOI":"10.1016\/j.drup.2011.02.003"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Giannakaki V, Miyakis S. Novel antimicrobial agents against multi-drug-resistant gram-positive bacteria: an overview. Recent Pat Antiinfect Drug Discov. 2012;7(3):182-188. doi: 10.2174\/157489112803521959.","DOI":"10.2174\/157489112803521959"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Haste NM, Thienphrapa W, Tran DN, et al. Activity of the thiopeptide antibiotic nosiheptide against contemporary strains of methicillin-resistant Staphylococcus aureus. J Antibiot. 2012; 65(12): 593-598. doi: 10.1038\/ja.2012.77","DOI":"10.1038\/ja.2012.77"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Iszatt JJ, Larcombe AN, Chan H-K, Stick SM, Garratt LW, Kicic A. Phage Therapy for Multi-Drug-Resistant Respiratory Tract Infections. Viruses. 2021 Sep 11;13(9): 809. doi: 10.3390\/v13091809.","DOI":"10.3390\/v13091809"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Huang DB, Morrissey I, Murphy T, et al. Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres. Eur J Clin Microbiol Infect Dis. 2018 Apr; 37(4): 673-678. doi: 10.1007\/s10096-017-3159-5.","DOI":"10.1007\/s10096-017-3159-5"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Jabes D. The antibiotic R&D pipeline: an update. Current opinion in microbiology. 2011;14(5):564-569. doi: 10.1016\/j.mib.2011.08.002.","DOI":"10.1016\/j.mib.2011.08.002"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Li W, Hadjigol S, Mazo AR, et al. Star-Peptide Polymers are Multi-Drug-Resistant Gram-Positive Bacteria Killers. ACS Appl Mater Interfaces. 2022 Jun 8;14(22):25025-25041. doi: 10.1021\/acsami.1c23734.","DOI":"10.1021\/acsami.1c23734"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther. 2018;16(4):259-268. doi: 10.1080\/14787210.2018.1441024.","DOI":"10.1080\/14787210.2018.1441024"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Mazumdar A, Haddad Y, Sur VP, et al. Characterization and in vitro Analysis of Probiotic-Derived Peptides Against Multi Drug Resistance Bacterial Infections. Front Microbiol. 2020 Aug 25;11:1963. doi: 10.3389\/fmicb.2020.01963","DOI":"10.3389\/fmicb.2020.01963"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Nale JY, Clokie MR. Preclinical data and safety assessment of phage therapy in humans. Curr Opin Biotechnol. 2021;68:310-317. doi: 10.1016\/j.copbio.2021.03.002","DOI":"10.1016\/j.copbio.2021.03.002"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Pasberg-Gauhl C. A need for new generation antibiotics against MRSA resistant bacteria. Drug Disc Today Technol. 2014;11:109-116. doi: 10.1016\/j.ddtec.2014.04.001.","DOI":"10.1016\/j.ddtec.2014.04.001"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Pezzanite LM, Chow L, Phillips J, et al. TLR-activated mesenchymal stromal cell therapy and antibiotics to treat multi-drug resistant Staphylococcal septic arthritis in an equine model. Ann Transl Med. 2022 Nov;10(21):1157. doi: 10.21037\/atm-22-1746.","DOI":"10.21037\/atm-22-1746"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:48:13Z","timestamp":1746445693000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i2net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202502108","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}